

सीएसआईआर – कोशिकीय एवं आणविक जीव विज्ञान केन्द्र
CSIR-Centre for Cellular & Molecular Biology
उप्पल रोड, हैदराबाद – 500007 (तेलंगाना), भारत
UPPAL ROAD, HYDERABAD 500 007, Telangana, INDIA
फ़ोन/Ph: 91-40-27192681/5541, फ़ैक्स / Fax: 91-40-27160252,
इ-मेल/E-Mail: bdg@ccmb.res.in / abs@ccmb.res.in

Expression of Interest (Eoi) is invited by Director, CSIR-CCMB from original Equipment Manufacturers/ service providers having global footprint for providing services for "**Newborn Screening for metabolic disorders**" to be carried out through CE Mark or FDA approved IVD platforms and reagents.

About CCMB

CSIR-Centre for Cellular & Molecular Biology (CCMB), Hyderabad is a premier research organization in frontier areas of modern biology. The objectives of the Centre are to conduct high quality basic research and training in frontier areas of modern biology, and promote centralized national facilities for new and modern techniques in the inter-disciplinary areas of biology.

About Project

Inborn errors of metabolism though individually rare, collectively and along with certain endocrinopathies, hearing loss and heart defects are the common causes of neonatal morbidity and mortality. Newborn screening is an important public health strategy to detect these disorders at the earliest stage and prevent irreversible damage from occurring to the babies by instituting appropriate therapies. Universal newborn screening, though differing in the number of conditions included, is prevalent in most developed countries since later half of 20th century. However, in India these efforts have largely been restricted to few small scale studies and are impeded by paucity of sufficient data.

CCMB has been actively involved in providing diagnostic services for human genetic disorders in addition to doing outstanding research on them for the past few decades. These services involved molecular testing for ~30 monogenic disorders and provision of cytogenetic services. Recently NGS based diagnostic services have been started as well. In this context, in order to achieve its larger goal of contributing to improving the health care in the country and decrease neonatal and infantile morbidity and mortality, CCMB is interested in initiating a newborn screening program from its campus in Hyderabad. Phase I of the project involves testing of newborn babies for the common disorders like congenital hypothyroidism, CAH, Galactosemia, G6PD deficiency and certain easily treatable conditions like biotinidase deficiency. Phase II of the project involves doing extended newborn screening by including TMS based testing for aminoacidopathies and fatty acid disorders. The data that would be generated would be useful for creating more focused NBS programs for the population at large. The project aims to screen about 2 lakh babies in about 2 years of initiation.

CCMB is looking forward to partner with original Equipment Manufacturers/ service providers (their duly authorized Indian Agents) who are having proven experience of at least 2-3 years of rendering similar services of "**Newborn Screening for Metabolic Disorders**" to be carried through CE Mark or FDA approved IVD platforms to any major Government/private organizations, reputed hospitals, etc. The firm shall be willing to offer services to install their equipment with trained and qualified manpower at CCMB, Annexe II, Uppal, Hyderabad-500039 to carry out Newborn Screening for CCMB's Diagnostics and R&D requirement on mutually agreed charges. CCMB will provide space and infrastructural support. The Bidder will be free to cater to third part services on charges fixed by them on mutually agreed term, which may include revenue sharing arrangement also.

CCMB's Responsibility

CCMB shall provide space, electricity and the required infrastructural support for collection & screening of samples procured from various hospitals for its Newborn Screening programme.

Bidder/ Service Providers' Responsibility

Bidder will be required to provide all the necessary equipment, accessories, reagents & any other consumables/material required for the said Newborn Screening. The bidder shall also provide adequate number of trained and qualified manpower to run the facility and also furnish the reports as per CCMB requirement to CCMB Scientists. All the cost towards day-to-day operation of the facility & generating reports would be the sole responsibility of the bidder.

Bidders' Experience and Platform to be used

Bidder should have proven experience of at least 2-3 years of rendering similar services of "**Newborn Screening for Metabolic Disorders**" to be carried out through CE Mark or FDA approved IVD platforms. It would be desirable for the bidder to have experience in working with state government institutes and hospitals working in similar area. Company with research and development mindset and inclination can help this technical collaboration better.

The detailed terms and conditions for the proposed technical collaboration/ partnership between CCMB and the bidder would be decided based on mutually agreed terms after identification of suitable collaborator/ partner at the time of entering into MOU.

Bidders who desire to become a prospective collaborator/ partner of CCMB in proposed R&D initiative and coming forward for technical presentation on 19th November 2019 shall inform this office by e-mail/post through written confirmation on or before 16th November 2019 enabling this office to make suitable arrangement accordingly. They are advised to have a power point technical presentation on the subject and also to carry the relevant documents and literature in support of their capability and experience to execute the Project.



(Dr A B Siva)

Head, Business Development Group (BDG)

Dr. Archana Bharadwaj Siva
Principal Scientist
Head-HRG & Business Development
Centre For Cellular and Molecular Biology
Uppal Road, Hyderabad - 500 007.